Hyderabad: PLAYER PHARMA MSN Laboratories PVT Ltd (MSN) has signed a license agreement with the Organization of Research & Defense Development (DRODO) for the manufacture, distribution and marketing of Covid-19 drugs for 2-deoxy-d-glucose drug (2-DG) in India.
Oral medicine has been given permission by the drug controller General India (DCGI) for emergency use as an additional therapy in medium-sized Covid-19 patients.
MSN said it would launch a drug under the name of the MSN 2D brand in the form of sachet as a product twice a day with a strength of 2.34 g.
This drug comes in the form of powder and must be taken by dissolving in water.
It works by accumulating in the cells that are infected with viruses and prevent virus growth by stopping energy production and viral synthesis.
MSN said while it had launched anti-virus drugs such as Oseltamivir capsules and anti-covid drugs such as favipiravir and baricatic and antifungal drugs such as posaconazole in the fight against Covid-19, he also conducted clinical trials for investigative drugs.
This includes Aviptadil who conducted clinical trials in severe hospital patients and with Molnupiravir in covid-19 patients who were lightweight and moderate.